Cardiac Markers

I. Cardiac Markers in Clinical Practice.- 1 Early Detection of Myocardial Necrosis in the Emergency Setting and Utility of Serum Biomarkers in Chest Pain Unit Protocols.- 2 Management of Acute Coronary Syndromes.- 3 Evolution of Cardiac Markers in Clinical Trials.- 4 Assessing Reperfusion and Prognostic Infarct Sizing with Biochemical Markers: Practice and Promise.- 5 The Use of Cardiac Biomarkers to Detect Myocardial Damage Induced by Chemotherapeutic Agents.- 6 The Use of Biomarkers to Provide Diagnostic and Prognostic Information Following Cardiac Surgery.- II. Clinical Use for Cardiac Troponins.- 7 Cardiac Troponins: Exploiting the Diagnostic Potential of Disease-Induced Protein Modifications.- 8 Cardiac Troponin Testing in Renal Failure and Skeletal Muscle Disease Patients.- 9 Cardiac-Specific Troponins Beyond Ischemic Heart Disease.- III. Analytical Issues for Cardiac Markers.- 10 Antibody Selection Strategies in Cardiac Troponin Assays.- 11 Interferences in Immunoassays for Cardiac Troponin.- 12 Cardiac Marker Measurement by Point-of-Care Testing.- 13 Standardization of Cardiac Markers.- 14 Analytical Issues and the Evolution of Cutoff Concentrations for Cardiac Markers.- IV. Early Cardiac Markers of Myocardial Ischemia and Risk Stratification.- 15 Rationale for the Early Clinical Application of Markers of Ischemia in Patients with Suspected Acute Coronary Syndromes.- 16 Ischemia-Modified Albumin, Free Fatty Acids, Whole Blood Choline, B-Type Natriuretic Peptide, Glycogen Phosphorylase BB, and Cardiac Troponin.- 17 C-Reactive Protein for Primary Risk Assessment.- 18 Prognostic Role of Plasma High-Sensitivity C-Reactive Protein Levels in Acute Coronary Syndromes.- 19 Preanalytic and Analytic Sources of Variations in C-Reactive Protein Measurement.- 20 Fatty Acid Binding Protein as an Early Plasma Marker of Myocardial Ischemia and Risk Stratification.- 21 Oxidized Low-Density Lipoprotein and Malondialdehyde-Modified Low-Density Lipoprotein in Patients with Coronary Artery Disease.- V. Cardiac Markers of Congestive Heart Failure.- 22 Pathophysiology of Heart Failure.- 23 B-Type Natriuretic Peptide: Biochemistry and Measurement.- 24 B-Type Natriuretic Peptide in the Diagnoses and Management of Congestive Heart Failure.- 25 Monitoring Efficacy of Treatment with Brain Natriuretic Peptide.- 26 N-Terminal Pro-B-Type Natriuretic Peptide.- VI. Role of Infectious Diseases and Genetics in Heart Disease.- 27 Infectious Diseases in the Etiology of Atherosclerosis and Acute Coronary Syndromes: Focus on Chlamydia pneumoniae.- 28 Polymorphisms Related to Acute Coronary Syndromes and Heart Failure: Potential Targets for Pharmacogenomics.